The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal
Status Awaiting development
Decision None selected
Process TA
ID number 2720

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 November 2020 Following the written consultation on the draft scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel in October 2020. The report included advice and recommendations to aid the decision-making process as to whether the topic should continue to be evaluated in the NICE work programme. The Topic Selection Oversight Panel concluded that an appraisal of ibalizumab in combination with other antiretroviral treatment for multidrug-resistant HIV-1 would be of limited value to the NHS at this time and therefore the topic will not progress any further
03 August 2020 (10:00) Scoping workshop
17 June 2020 - 15 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual